Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Shionogi to Acquire 9 Products from Victory Pharma of the US
August 1, 2011
- FDA's Advisory Committee Does Not Recommend Approval of Dapagliflozin
August 1, 2011
- Korosho, PMDA Providing Risk Info on Drugs Under Review on Websites
August 1, 2011
- LTT Bio-Pharma to License Inhalant PC-SOD to CKD in South Korea
August 1, 2011
- Transfer of Part of PMDA Functions to Osaka Proposed in Kansai Sogo Tokku Plan
August 1, 2011
- Astellas Licenses Transplant Viremia Prevention Vaccine from Vical
August 1, 2011
- Chugai Applies for Approval of Pulmozyme for Cystic Fibrosis
August 1, 2011
- Mochida, MTPC to Launch Lexapro on Aug. 22
August 1, 2011
- Sodium Phenylbutyrate from CMIC Designated as Orphan Drug
August 1, 2011
- Nihon Chouzai to Introduce Finger Vein Authentication at All Stores
August 1, 2011
- NPhA Withdraws Request to Refrain from Offering Points for Dispensing Services
August 1, 2011
- Ain Pharmaciez to Improve Its Services for Patients Using Smart Phones
August 1, 2011
- Rivaroxaban's Safety Found Non-inferior to Warfarin in Domestic PIII Study
August 1, 2011
- Pfizer Obtains Approval for Generics of 14 APIs
August 1, 2011
- US FDA Announces Draft Guidance for Simultaneous Development of Therapeutics and Companion Diagnostic Devices
August 1, 2011
- Daiichi Sankyo Espha to Deal with Both Long-listed Products, Generics
August 1, 2011
- Biosimilars Optimize Healthcare Costs: JSGM Seminar
August 1, 2011
- AZ, NCC Announce Comprehensive Agreement for Development of Anticancer Drugs
August 1, 2011
- Eisai Obtains Marketing Rights to 2 Drugs from Orion in China
July 25, 2011
- Aricept Generics Approved from 33 Companies
July 25, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…